Journal
JOURNAL OF NEUROLOGY
Volume 265, Issue 11, Pages 2684-2687Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-018-9048-8
Keywords
Clinically isolated syndrome; Multiple sclerosis; Conversion; Diagnostic criteria; Dissemination in space; Dissemination in time; Symptomatic gadolinium enhancing lesion; Oligoclonal bands
Categories
Funding
- Novartis
- Teva
- Sanofi Genzyme
- Almirall
- Associazione Italiana Sclerosi Multipla (AISM)
- Genzyme
- Bayer Schering
- Biogen-Dompe
- Boehringer Ingelheim
- Lundbeck
- Merck-Serono
- Sigma-Tau
- UCB Pharma
- Biogen Idec
- Biogen
- Merck Serono
- Eisai
- Sanofi-Aventis
- Roche
Ask authors/readers for more resources
Objectives To investigate the impact of the 2017 revisions of McDonald criteria on the diagnosis of multiple sclerosis (MS) in a cohort of patients with clinically isolated syndrome (CIS) and dissemination in space (DIS) of demyelinating lesions. Methods We retrospectively analyzed 137 patients with CIS+DIS from two Italian MS centers. Results Application of the 2017 revisions of McDonald criteria in our cohort led to a diagnosis of MS in 82.5% of the patients who could have not been diagnosed with MS according to the previous criteria at the time of the first demyelinating event. After a follow-up of 3.8 +/- 2.9 years, 85.8% of these patients eventually satisfied also the previous (2010) criteria. Conclusions Application of the 2017 revisions of McDonald criteria results in an earlier diagnosis of MS in a large percentage of CIS patients destined to convert to MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available